Home » Archive

News

Marketwire, News, Syndication »

Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2011 Financial Results

Posted by Mary Canady March 9th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 9, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and ann…

More...

Marketwire, News, Syndication »

Cytori Provides Strategic Outlook, Near Term Objectives and Reports Year-End 2011 Results

Posted by Mary Canady March 8th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 8, 2012) – In 2011, Cytori Therapeutics (NASDAQ: CYTX) achieved important objectives towards validating Celution® technology in multiple large market indications, clarified the U.S. cardiovascular pathway with FDA, …

More...

Diagnostics, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Aragon, Illumina, CareFusion, & More

Posted by sandiegobiotech March 8th, 2012 .
No Comments

We saw some sizable deals in the life sciences domain over the past week, including an interesting partnership that Domain Associates formed with Moscow-based Rusnano. —The venture capital firm…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Medistem Signs Exclusive Worldwide License With Yale University for Treatment of Type 1 Diabetes Using Stem Cells

Posted by Mary Canady March 7th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 7, 2012) – Medistem Inc. (PINKSHEETS: MEDS) and Yale University have signed an exclusive worldwide licensing agreement covering the generation of pancreatic islets from stem cells such as the Endometrial Regenerative…

More...

Marketwire, News, Syndication »

Medistem Signs Exclusive Worldwide License With Yale University for Treatment of Type 1 Diabetes Using Stem Cells

Posted by Mary Canady March 7th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 7, 2012) – Medistem Inc. (PINKSHEETS: MEDS) and Yale University have signed an exclusive worldwide licensing agreement covering the generation of pancreatic islets from stem cells such as the Endometrial Regenerative…

More...

News, Syndication, Xconomy »

The Thinking Behind Domain’s $760M Life Sciences Deal in Russia

Posted by sandiegobiotech March 7th, 2012 .
No Comments

The partnership that the life sciences venture firm Domain Associates and the Russian state technology firm Rusnano disclosed yesterday began almost two years ago, at a time when the U.S. financial…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Senomyx to Webcast Corporate Presentation at the ROTH 24th Annual OC Growth Stock Conference

Posted by Mary Canady March 7th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 7, 2012) – Senomyx, Inc. (NASDAQ: SNMX), a leading company focused on using proprietary taste receptor technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply indus…

More...

News, Syndication, Xconomy »

Disease Foundations Play Growing Role in Biotech Business Model

Posted by sandiegobiotech March 6th, 2012 .
No Comments

California is home to the largest concentration of biotechnology companies in the world. They are responsible for 27 percent of the nation’s biomedical pipeline and they received $2.6 billion in…

[[Click headline to continue reading.]]

More...

Marketwire, News, NYSE:PFE, Syndication »

Lpath Raises $9.3 Million in Equity Financing

Posted by Mary Canady March 6th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Mar 6, 2012) – Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has entered into subscription agreements with various investors to raise approximately $9.3 million through the sal…

More...

Drug Development, News, Syndication, Xconomy »

San Diego’s Aragon Raises $42 Million, Targets Hormone-Driven Cancers

Posted by sandiegobiotech March 5th, 2012 .
No Comments

Aragon Pharmaceuticals, a San Diego startup targeting hormone-driven cancers, has raised $42 million in a Series C financing led by a new investor, the Topspin Fund, a Long Island, NY-based firm…

[[Click headline to continue reading.]]

More...